ÑòÍÕVHH SingleB?¿ìËÙ·¢ÏÖ
ÑòÍÕµÈÂæÍտƶ¯ÎïÌåÄÚÌìÈ»´æÔÚȱʧÇáÁ´¼°ÖØÁ´CH1½á¹¹µ«ÍêÈ«±£Áô¿¹Ô½áºÏ»îÐÔµÄÖØÁ´¿¹Ì壨HCAb£©£¬ÆäÖÐÌØÒìÐÔ½áºÏ¿¹ÔµÄÖØÁ´¿É±äÇø³ÆΪµ¥Óò¿¹Ì壨sdAbs£©£¬¼´ÄÉÃ׿¹Ì壨Nanobody£©£¬¼ò³ÆVHH£¬ÊÇ×îСµ¥Ôª¿¹Ô½áºÏƬ¶Î¡£
µÂÌ©ÉúÎï»ùÓÚÁ÷ʽϸ°û·Öѡƽ̨ºÍDeepLight?ɸѡƽ̨£¬ÌṩÑòÍÕVHH SingleB?¿ìËÙÖƱ¸·þÎñ£¬´ÓÑòÍÕÃâÒß¡¢¼ÇÒäBϸ°ûºÍ½¬Ï¸°û˫ɸѡ¡¢BGE?¸ßͨÁ¿±í´ï¡¢±í´ï¼ø¶¨µ½´¿»¯£¬È«Á÷³Ì½öÐè90Ìì¡£
VHH¶ÀÌØÓÅÊÆ
Conventional antibody
150kDa
Camelid heavy-chain antibody
95kDa
Fv
30kDa
scFv
30kDa
dsFv
30kDa
Nanobody
12-14kDa
VHH»ùÓڽṹÌØÒìÐÔ£¬¼¯´«Í³¿¹ÌåÓëС·Ö×ÓÒ©ÎïµÄÓŵãΪһÌ壺
- µÍ·Ö×ÓÁ¿£º½öΪ12-14kDa£¬×éÖ¯´©Í¸Á¦Ç¿£¬¹ã·ºÓ¦ÓÃÓÚÖ×ÁöÕï¶ÏÖÎÁƺͷÖ×ÓÓ°ÏñµÈ¡£
- ½á¹¹¼òµ¥£ºÒ×ÓÚ½øÐлùÒò¹¤³Ì¸ÄÔ죬ÓëÈËVHͬԴÐÔ80%£¬Ò×ÈËÔ´»¯¡£
- ÃâÒßÔÐԵͣº²»º¬Fcβ¶Ë£¬²»»áÒý·¢Ïà¹ØµÄÃâÒßÔÐÔ£¬³ÉÒ©ÐԸߡ£
- ÌØÒìÐԸߣºCDR3Çø½Ï³¤£¬¿ÉÐγÉָ״͹»·½øÒ»²½Ê¶±ðÒþ²Ø¿¹Ô±íλ¡£
- ¸ßÇ×Ë®ÐÔ£ºFR2ÇøÇ×Ë®°±»ùËᱣ֤ˮÈÜÐÔ£¬¿¹Ìå²»Ò×¾Û¼¯¡£
- ÖƱ¸¼òµ¥£º¿É´óÁ¿±í´ï£¬¹¤Òµ»¯·Å´óÉú²ú³É±¾µÍÖÜÆڶ̡£
- ¸ßÎȶ¨ÐÔ£ºÒ×´¢´æ£¬¿ÉÄÍÊܸßΡ¢Ç¿Ëᡢǿ¼îµÈÖ±äÐÔÌõ¼þ¡£
·þÎñÓÅÊÆ
90Ìì¸ß½»¸¶
½»¸¶50ÖêFACS binder
¼°VHHÐòÁÐ
¡°1+1¡±Ë«±£ÕÏ
¼ÇÒäBϸ°û&½¬Ï¸°û
˫ɸѡ˫±£ÕÏ
Ç°Öù¦ÄÜɸѡ
DeepLight?ƽ̨
ʵÏÖ¶àÖÖon-chip assay
ÌìÈ»³ÉÊì
¿¹ÌåÇ׺ÍÁ¦¸ü¸ß
»ù±¾Ïû³ýÃâÒßÔÐÔ
·þÎñÁ÷³Ì
·þÎñÄÚÈÝ
| ½×¶Î |
·þÎñÄÚÈÝ |
ÖÜÆÚ |
½»¸¶ |
| ½×¶Î¢ñ ¶¯ÎïÃâÒß |
- ¿¹ÔÖƱ¸£¨¿ÉÑ¡£©
- ÑòÍÕÃâÒß
- Ч¼Û¼ì²â
|
8~9ÖÜ |
Premium Package
- ´óÓÚ50ÖêFACS binder
- ±£ÕÏÐòÁжàÑùÐÔ
- VHHÐòÁм°±í´ïÖÊÁ£
- ÖÊÁ¿¼ìÑ鱨¸æ£¨CoA£©
Economic Package
- 5-10ÖêELISAÑôÐÔ¿Ë¡
- VHHÐòÁм°±í´ïÖÊÁ£
- Ñ¡1Öê´¿»¯1mg¿¹Ìå
- ÖÊÁ¿¼ìÑ鱨¸æ£¨CoA£©
|
| ½×¶Î¢ò ¡°1+1¡±Ë«É¸Ñ¡ |
|
1Ìì |
| ½×¶Î¢ó BGE?¸ßͨÁ¿±í´ï¼°¹¦ÄÜÑéÖ¤ |
|
1~2ÖÜ |
| ½×¶Î¢ô ÄÉÃ׿¹Ìå»ùÒò²âÐò |
|
1ÖÜ |
| ½×¶Î¢õ ÖØ×鿹Ìå±í´ïÓë´¿»¯£¨¿ÉÑ¡£© |
- תȾ¼¶ÖÊÁ£ÖƱ¸
- ˲ʱתȾ±í´ï
- ¸ßͨÁ¿´¿»¯
- ÎÞÄÚ¶¾ËØ´¿»¯
|
Ïêѯ |
·þÎñ°¸Àý
Fig 1. FACS sorting of MBCs
Fig 2. FACS binding assay
The obtained VHHs in one plate were tested by FACS assay and showed high affinity to antigen and high positive rate.
Ïà¹Ø·þÎñ
ËÕ¹«Íø°²±¸32011202001300
ËÕICP±¸2021019379ºÅ-1
|